Medtronic confronts $7 million patent lawsuit; Accelr8 completes $35M stock sale;

@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: SCOTUS upheld the whole national health reform law. The med device industry will keep opposing one of its major parts: the 2.3% industry tax. | Follow @MarkHFierce

 @DamianFierce: Changing its tune, Medtronic will sit down with the man who figured out how to hack one of its insulin pumps. Article | Follow @DamianFierce

> The New England Research Institutes in Watertown won an $18 million contract from the National Institutes of Health to develop pediatric circulatory support devices. NERI is a CRO that runs clinical trials for medical device and biotech companies. Story

> Medtronic ($MDT) faces a lawsuit from St. Louis University that accuses the company of depriving the school of at least $7 million in royalties regarding surgical navigation and imaging technology licenses. Story

> Israel's NLT Spine has generated encouraging initial clinical results from its spinal fusion device. Release

> Grove Instruments recently completed initial clinical testing of a bloodless glucometer that uses light to check blood sugar in no more than 20 seconds. Story

> Bausch + Lomb gained FDA clearance for a new one day disposable contact lens. Release

Biotech News

 @FierceBiotech: Justice Roberts is a popular man in biotech today. Biosimilars pathway and 12 year market exclusivity appear intact. | Follow @FierceBiotech

 @JohnCFierce: Quick snap on biopharma implications: Supreme Court upholds ACA, biotech threats disappear. News | Follow @JohnCFierce

> FDA offers Bayer, Onyx fast review for regorafenib. Item

> Arena basks in spotlight as FDA OKs obesity drug lorcaserin. Article

> In fresh setback Anthera shares blitzed as lupus drug flunks PhIIb. Story

> Success in PhII clears Vertex's path to late-stage study of cystic fibrosis combo. News

Pharma News

 @FiercePharma: Our quick take: With individual mandate upheld, pharma gets its new patients. More | Follow @FiercePharma

> With individual mandate upheld, pharma gets its new patients. Report

> Arena's next challenge: Build up Belviq sales. Story

> Purdue fights to extend OxyContin monopoly. Article

> Shire's Gaucher drug beats Cerezyme in bone study. News

CRO News

 @NesaNFierce: As an IU Hoosier, it's really nice to publish good news on Indiana biotech. News | Follow @NesaNFierce

> CROs or Pharma: The great innovation debate. Item

> CMO Shamrock hit with FDA warning over mislabeling. Story

> Top CRO executives predict industry's future. More

> NERI secures $18M pediatric clinical trial contract from NIH. News

Vaccines News

> Swine flu shots a success for Scotland. More

> BioDiem steps closer to a dengue vaccine. Story

> Sanofi's Hexaxim vax gets EMA thumbs up. News

> Cuban hepatitis B vax cuts disease. Item

Pharma Manufacturing News

> Daiichi Sankyo opens first U.S. manufacturing plant. News

> Merck closing Cherokee fermentation operations. More

> AMAG closing plant, moving to contract manufacturing. News

And Finally... Accelr8 Technology has consummated a deal with an investment group that will purchase up to $35 million in common stock. The company plans to use the funds to finish developing and then launch a new diagnostic system designed to identify bacterial and fungal pathogens and test their antibiotic resistance. Release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.